IMAXIO is an integrated biopharmaceutical company operating in the therapeutic and diagnostic fields.

IMAXIO relies on several proprietary technology platforms specializing in protein engineering and genomics to develop innovative diagnostic tests and therapies centered on infectious diseases and oncology.

IMAXIO is a member of Lyonbiopôle, a pole of excellence in healthcare and of Cancéropôle Lyon Auvergne Rhône-Alpes (CLARA), a structure of cancer research.